The Cambridge-based nanomedicine developer has raised capital to expand its laboratory facilities and accelerate product development for its polyNaut technology.
"We are also proud to be working with the Cystic Fibrosis Foundation on one of our key pipeline programmes, underscoring our commitment to advancing treatments for people with cystic fibrosis and other unmet clinical needs. This fundraise marks a pivotal moment in ViaNautis’s journey and we look forward to advancing the field of gene therapy, while creating substantial value for our shareholders."
Mercia Ventures led the Series A round to support product development and industry partnerships.
"Risk Ledger provides us with a more holistic, real time view of our complex supply chain, helping to identify and remediate potential vulnerabilities and issues early."
— David Malkin, former Divisional Information Security Officer at the UK Health Security Agency
The Series A round was led by 6 Degrees Capital, Hambro Perks, and Solano Partners.
"We are thrilled to have the support and trust of our investors who help us propel technology-led security in short-term rental making it more accessible for property managers, hosts, and guests around the globe."
The investment was led by Amadeus Capital Partners and Praetura Ventures to drive international expansion and product development.
"We process thousands of claims globally with our solution every day and millions of policyholders receive fast and accurate decisions as a result. This investment will enable us to grow further into international markets and continue to invest in our AI-led product to drive towards our vision to ‘Make every claim better‘."